| アブストラクト | Rivaroxaban has become an alternative to vitamin K antagonists, which are considered to be at higher risk of drug-drug interactions (DDI) and more difficult to use. However, DDI do occur. We systematically reviewed studies that evaluated them and analysed DDI and subsequent adverse drug reactions (ADR) reported in spontaneous reports and VigiBase. We systematically searched articles that explored DDI with rivaroxaban up to 20 August 2018 via Medline, Embase and Google Scholar. Data from VigiBase came from spontaneous reports recovered up to 2 January 2018, where Omega was used to detect signals and identify potential interactions in terms of triplets with two drugs and one ADR. We identified 31 studies and 28 case reports. Studies showed significant variation in the pharmacokinetic for rivaroxaban, and an increased risk of haemorrhage or thromboembolic events due to DDI was highlighted in case reports. From VigiBase, a total of 21,261 triplets were analysed and the most reported was rivaroxaban-aspirin-gastrointestinal haemorrhage. In VigiBase, only 34.8% of the DDI reported were described or understood, and most were pharmacodynamic DDI. These data suggest that rivaroxaban should be considered to have significant potential for DDI, especially with CYP3A/P-gp modulators or with drugs that impair haemostasis. |
|---|
| ジャーナル名 | Journal of personalized medicine |
|---|
| Pubmed追加日 | 2021/4/4 |
|---|
| 投稿者 | Fernandez, Silvia; Lenoir, Camille; Samer, Caroline Flora; Rollason, Victoria |
|---|
| 組織名 | Department of Anesthesiology, Pharmacology, Intensive Care and Emergency;Medicine, Division of Clinical Pharmacology and Toxicology, Geneva University;Hospitals, 1205 Geneva, Switzerland.;Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University;of Geneva, 1206 Geneva, Switzerland. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33808367/ |
|---|
